Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

NCT: NCT03738553 · TERMINATED

NCT IDNCT03738553
StatusTERMINATED
Start Date2013-08
Completion2026-03-01

Brief Summary

This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.

Frequently Asked Questions

What is Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy?

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy is a clinical trial registered under NCT03738553. Current status: TERMINATED.

What is the status of NCT03738553?

The current status of NCT03738553 (Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy) is: TERMINATED.

When did Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy start?

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy started on 2013-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑